In today’s session Eli Lilly and Co (LLY) registered an unusually high (2,118) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious LLY increase. With 2,118 contracts traded and 69564 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: LLY161021C00080000 closed last at: $0.95 or 27.5% down. About 1.87 million shares traded hands. Eli Lilly and Co (NYSE:LLY) has risen 7.25% since March 14, 2016 and is uptrending. It has outperformed by 1.64% the S&P500.
Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on October, 25 before the open. They expect $0.94 earnings per share, up 5.62% or $0.05 from last year’s $0.89 per share. LLY’s profit will be $1.03B for 20.93 P/E if the $0.94 EPS becomes a reality. After $0.86 actual earnings per share reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 9.30% EPS growth.
Eli Lilly and Co (NYSE:LLY) Ratings Coverage
Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. BMO Capital Markets upgraded the stock to “Outperform” rating in Monday, November 16 report. The rating was maintained by Jefferies with “Buy” on Friday, September 18. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, October 13. The firm has “Buy” rating by Berenberg given on Thursday, August 27. Atlantic Securities initiated Eli Lilly and Co (NYSE:LLY) rating on Friday, December 18. Atlantic Securities has “Overweight” rating and $100 price target. The rating was upgraded by Barclays Capital to “Overweight” on Tuesday, December 1. The company was upgraded on Tuesday, December 8 by Credit Suisse. On Monday, December 28 the stock rating was maintained by Leerink Swann with “Outperform”. Leerink Swann maintained the stock with “Outperform” rating in Monday, May 2 report. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Buy”.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”
Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.36, from 0.71 in 2016Q1. The ratio improved, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Deere accumulated 77,092 shares or 0.33% of the stock. Da Davidson owns 26,794 shares or 0.06% of their US portfolio. Maryland reported 35,543 shares or 0.44% of all its holdings. Moreover, Tokio Marine Asset Mngmt has 0.74% invested in Eli Lilly and Co (NYSE:LLY) for 91,695 shares. Riggs Asset Managment holds 0% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 31 shares. Bedrijfstakpensioenfonds Voor De Media Pno holds 212,100 shares or 2.25% of its portfolio. Wetherby Asset Mngmt Incorporated holds 13,996 shares or 0.24% of its portfolio. Rockland Tru Company reported 30,000 shares or 0.39% of all its holdings. Moreover, Homrich Berg has 0.09% invested in Eli Lilly and Co (NYSE:LLY) for 12,353 shares. Harvey Inv Ltd Liability Corporation has 14,390 shares for 0.25% of their US portfolio. Johnson Inv Counsel Inc last reported 0.08% of its portfolio in the stock. The New York-based Goldman Sachs Inc has invested 0.18% in Eli Lilly and Co (NYSE:LLY). Alpha Windward Ltd Liability Corp, a Massachusetts-based fund reported 2,114 shares. Moreover, Marietta Prtn Ltd Limited Liability Company has 0.11% invested in Eli Lilly and Co (NYSE:LLY) for 4,025 shares. Moreover, Joel Isaacson And Company has 0.06% invested in Eli Lilly and Co (NYSE:LLY) for 3,868 shares.
Insider Transactions: Since April 27, 2016, the stock had 1 buy, and 14 sales for $149.60 million net activity. 1,213 shares were sold by Zakrowski Donald A, worth $100,873. Shares for $19.89 million were sold by LILLY ENDOWMENT INC on Thursday, July 28. $915,240 worth of Eli Lilly and Co (NYSE:LLY) was sold by Zulueta Alfonso G on Wednesday, April 27. On Tuesday, October 4 Crowe Maria A sold $182,927 worth of the stock or 2,248 shares. 992 shares with value of $73,180 were sold by Barnes Melissa S on Friday, June 10. $205,875 worth of shares were bought by TAI JACKSON P on Friday, August 12.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $86.07 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 33.92 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
LLY Company Profile
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
More recent Eli Lilly and Co (NYSE:LLY) news were published by: Wsj.com which released: “Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million” on October 05, 2016. Also Marketwatch.com published the news titled: “Eli Lilly’s Elanco to acquire Boheringer Inghelheim’s US rabies vaccine …” on October 05, 2016. Prnewswire.com‘s news article titled: “New Data on the Combination of Lilly’s ALIMTA® (pemetrexed) and Merck’s …” with publication date: October 09, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.